All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for TAKEDA PHARMACEUTICALS AMERICA, INC. · pharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Illinois · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 2

S 891
Bipartisan Health Care Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.